Immunotherapy for urological malignancies

Journal of Urology

Volumn 171, Issue 2 I, 2004, Pages 870-876

  Krejci, Kent G ^a   Markiewicz, Mary A ^a   Kwon, Eugene D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bladder; Immunotherapy; Kidney; Neoplasms; Prostate

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANDROGEN; B7 ANTIGEN; BCG VACCINE; CD28 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; CELL EXTRACT; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; FLT3 LIGAND; GAMMA INTERFERON; GLYCOPROTEIN P; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4; KEYHOLE LIMPET HEMOCYANIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; MUCIN 1; PROSTATE SPECIFIC ANTIGEN; RUBRATIN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; BLADDER CARCINOMA; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; KIDNEY CARCINOMA; MEDLINE; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROSTATE CARCINOMA;

EID: 0347759817     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000101161.17279.09     Document Type: Review

References (77)

1. American Cancer Society, http://www.cancer.org/. Accessed May 1, 2003
2. Kramer, G., Steiner, G. E., Sokol, P., Handisurya, A., Klingler, H. C., Maier, U. et al: Local intratumoral tumor necrosis factor-alpha and systemic IFN-alpha 2b in patients with locally advanced prostate cancer. J Interferon Cytokine Res, 21: 475, 2001
3. Belldegrun, A. S., Franklin, J. R., O'Donnell, M. A., Gomella, L. G., Klein, E., Neri, R. et al: Superficial bladder cancer: the role of interferon-α. J Urol, 159: 1793, 1998
4. Kalble, T., Beer, M., Mendoza, E., Ikinger, U., Link, M., Reichert, H. E. et al: BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study. Urologe A, 33: 133, 1994
5. Flanigan, R. C., Salmon, S. E., Blumenstein, B. A., Bearman, S. I., Roy, V., McGrath, P. C. et al: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell carcinoma. New Engl J Med, 345: 1655, 2001
6. Meredith, R. F., Khazaeli, M. B., Macey, D. J., Grizzle, W. E., Mayo, M., Schlom, J. et al: Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin Cancer Res, 5: 3254s, 1999
7. Murray, A., Simms, M. S., Scholfield, D. P., Vincent, R. M., Denton, G., Bishop, M. C. et al: Production and characterization of 188Re-C595 antibody for radioimmunotherapy of transitional cell bladder cancer. J Nucl Med, 42: 726, 2001
8. Hughes, O. D., Bishop, M. C., Perkins, A. C., Wastie, M. L., Denton, G., Price, M. R. et al: Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595. J Clin Oncol, 18: 363, 2000
9. Steffens, M. G., Boerman, O. C., de Mulder, P. H., Oyen, W. J., Buijs, W. C., Witjes, J. A. et al: Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res, 5: 3268s, 1999
10. Seliger, B., Rongcun, Y., Atkins, D., Hammers, S., Huber, C., Storkel, S. et al: HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int J Cancer, 87: 349, 2000
11. Kuhn, E. J., Kurnot, R. A., Sesterhenn, I. A., Chang, E. H., and Moul, J. W.: Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol, 150: 1427, 1993
12. Dinney, C. P., Parker, C., Dong, Z., Fan, D., Eve, B. Y., Bucana, C. et al: Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide. Clin Cancer Res, 3: 161, 1997
13. Agus, D. B., Scher, H. I., Higgins, B., Fox, W. D., Heller, G., Fazzari, M. et al: Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res, 59: 4761, 1999
14. Ross, S., Liu, V., Abulafia, R., Hogan, C., and Osband, M.: Adoptive immunotherapy of hormone-refractory, stage D2 prostate cancer using ex vivo activated autologous T cells (autolymphocyte therapy): results from a pilot study. Biotechnol Ther, 4: 197, 1993
15. Bukowski, R. M., Sharfman, W., Murthy, S., Rayman, P., Tubbs, R., Alexander, J. et al: Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Res, 51: 4199, 1991
16. Osband, M. E., Lavin, P. T., Babayan, R. K., Graham, S., Lamm, D. L., Parker, B. et al: Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet, 335: 994, 1990
17. Graham, S., Babayan, R. K., Lamm, D. L., Sawczuk, I., Ross, S. D., Lavin, P. T. et al: The use of ex vivo-activated memory T cells (auto lymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study. Semin Urol, 11: 27, 1993
18. Pollard, M. and Luckert, P. H.: The antimetastatic effect of IV-inoculated BCG on adenocarcinomas in the prostate-seminal vesicle complex of L-W rats. Anticancer Res, 14: 901, 1994
19. Lamm, D. L., Blumenstein, B. A., Crissman, J. D., Montie, J. E., Gottesman, J. E., Lowe, B. A. et al: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol, 163: 1124, 2000
20. Krege, S., Giani, G., Meyer, R., Otto, T., Rübben, H. et al: A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. J Urol, 156: 962, 1996
21. Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Montie, J. E., Scardino, P., Grossman, H. B. et al: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med, 325: 1205, 1991
22. Martínez-Piñeiro, J. A., Jiménez León, J., Martínez-Piñeiro, L., Jr., Fiter, L., Mosteiro, J. A., Navarro, J. et al: Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol, 143: 502, 1990
23. O'Donnell, M. A.: The genetic reconstruction of BCG as a new immunotherapeutic tool. Trends Biotechnol, 15: 512, 1997
24. O'Donnell, M. A., Krohn, J. and DeWolf, W. C.: Salvage intravesical therapy with interferon-α2B plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol, 166: 1300, 2001
25. de Reijke, T. M., de Boer, E. C., Schamhart, D. H. and Kurth, K. H.: Immunostimulation in the urinary bladder by local application of Nocardia rubra cell wall skeleton preparation (Rubratin) for superficial bladder cancer immunotherapy-a phase I/II study. Urol Res, 25: 117, 1997
26. Morales, A., Chin, J. L. and Ramsey, E. W. Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder: J Urol, 166: 1633, 2001
27. Hrouda, D., Baban, B., Dunsmuir, W. D., Kirby, R. S. and Dalgleish, A. G.: Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). Br J Urol, 82: 568, 1998
28. Olsson, C. A., Chute, R. and Rao, C. N.: Immunologic reduction of bladder cancer recurrence rate. J Urol, 111: 173, 1974
29. Lamm, D. L., Dehaven, J. I. and Riggs, D. R.: Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies. Eur Urol, suppl., 37: 41, 2000
30. Heinzer, H., Huland, E. and Huland, H.: Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer. World J Urol, 19: 111, 2001
31. Hofmockel, G., Langer, W., Theiss, M., Gruss, A. and Frohmüller, H. G. W.: Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-a and 5-fluorouracil. J Urol, 156: 18, 1996
32. Walther, M. M., Yang, J. C., Pass, H. I., Linehan, W. M. and Rosenberg, S. A.: Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol, 158: 1675, 1997
33. Wagner, J. R., Walther, M. M., Linehan, W. M., White, D. E., Rosenberg, S. A. and Yang, J. C.: Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol, 162: 43, 1999
34. Maffezzini, M., Simonato, A. and Fortis, C.: Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment. Prostate, 28: 282, 1996
35. Den Otter, W., Dobrowolski, Z., Bugajski, A., Papla, B., Van Der Meijden, A. P. M., Koten, J. W. et al: Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J Urol, 159: 1183, 1998
36. Coughlin, C. M., Salhany, K. E., Gee, M. S., LaTemple, D. C., Kotenko, S., Ma, X. et al: Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity, 9: 25, 1998
37. Nasu, Y., Bangma, C. H., Hull, G. W., Lee, H. M., Hu, J., Wang, J. et al: Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther, 6: 338: 1999
38. Wigginton, J. M., Komschlies, K. L., Back, T. C., Franco, J. L., Brunda, M. J. and Wiltrout, R. H.: Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst, 88: 38, 1996
39. Fehniger, T. A., Yu, H., Cooper, M. A., Suzuki, K., Shah, M. H., and Caligiuri, M. A.: Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo. J Immunol, 164: 1643, 2000
40. Suzuki, K., Nakazato, H., Matsui, H., Hasumi, M., Shibata, Y., Ito, K. et al: NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer. J Leukoc Biol, 69: 531, 2001
41. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K. et al: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA, 90: 3539, 1993
42. Salgaller, M. L. and Lodge, P. A.: Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J Surg Oncol, 68: 122, 1998
43. Dreicer, R., See, W. A., and Klein, E. A.: Phase II trial of GM-CSF in advanced prostate cancer. Invest New Drugs, 19: 261, 2001
44. Stravoravdi, P., Toliou, T., Kirtsis, P., Natsis, K., Konstandinidis, E., Barich, A. et al: A new approach in the management of urothelial tumors using GM-CSF on marker lesions: an ultrastructural and immunohistochemical study on the macrophage population in bladder mucosa. J Interferon Cytokine Res, 19: 221, 1999
45. Schmidinger, M., Steger, G., Wenzel, C., Locker, G. J., Budinsky, A. C., Brodowicz, T. et al: Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: results of a phase II trial. J Immunother, 24: 257, 2001
46. Kwon, E. D., Hurwitz, A. A., Foster, B. A., Madias, C., Feldhaus, A. L., Greenberg, N. M. et al: Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA, 94: 8099, 1997
47. Kwon, E. D., Foster, B. A., Hurwitz, A. A., Madias, C., Allison, J. P., Greenberg, N. M. et al: Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci USA, 96: 15074, 1999
48. Hurwitz, A. A., Foster, B. A., Kwon, E. D., Truong, T., Choi, E. M., Greenberg, N. M. et al: Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res, 60: 2444, 2000
49. Davis, T. A., Tchekmedyian, S., Korman, A., Keler, T., Deo, Y. and Small, E. J.: MDX-010 (human anti-CTLA4): a phase I trial in hormone refractory prostate carcinoma (HRPC). Am Soc Clin Oncol, 2002
50. Katzenwadel, A., Schleer, H., Gierschner, D., Wetterauer, U. and Elsasser-Beile, U.: Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer. Anticancer Res, 20: 1551, 2000
51. Heike, Y., Okumura, K. and Tsuruo, T.: Augmentation by bispecific F(ab′)2 reactive with P-glycoprotein and CD3 of cytotoxicity of human effector cells on P-glycoprotein positive human renal cancer cells. Jpn J Cancer Res, 83: 366, 1992
52. Mercader, M., Bodner, B. K., Moser, M. T., Kwon, P. S., Park, E. S., Manecke, R. G. et al: T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA, 98: 14565, 2001
53. Huang, A. Y., Bruce, A. T., Pardoll, D. M. and Levitsky, H. I.: Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med, 183: 769, 1996
54. Maraskovsky, E., Brasel, K., Teepe, M., Roux, E. R., Lyman, S. D., Shortman, K. et al: Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med, 184: 1953, 1996
55. Ciavarra, R. P., Somers, K. D., Brown, R. R., Glass, W. F., Consolvo, P. J., Wright, G. L. et al: Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer. Cancer Res, 60: 2081, 2000
56. Rini, B. I., Paintal, A., Vogelzang, N. J., Gajewski, T. F. and Stadler, W. M.: Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity. J Immunother, 25: 269, 2002
57. Galligioni, E., Quaia, M., Merlo, A., Carbone, A., Spada, A., Favaro, D. et al: Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer, 77: 2560, 1996
58. Hinkel, A., de Riese, W., Alefelder, J., Laumann, D., Falkenberg, F. W., Senge, T. et al: Active specific immunotherapy with an autologous virus-modified tumour cell vaccine in human renal cell carcinoma (RCC). Eur J Cancer, 31A: 1719, 1995
59. Simons, J. W., Mikhak, B., Chang, J. F., DeMarzo, A. M., Carducci, M. A., Lim, M. et al: Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res, 59: 5160, 1999
60. Simons, J. W., Jaffee, E. M., Weber, C. E., Levitsky, H. I., Nelson, W. G., Carducci, M. A. et al: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res, 57: 1537, 1997
61. Schendel, D. J., Frankenberger, B., Jantzer, P., Cayeux, S., Nobetaner, E., Willimsky, G. et al: Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse. Gene Ther, 7: 2007, 2000
62. McElrath, M. J.: Selection of potent immunological adjuvants for vaccine construction. Semin Cancer Biol, 6: 375, 1995
63. Mandelboim, O., Vadai, E., Fridkin, M., Katz-Hillel, A., Feldman, M., Berke, G. et al: Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat Med, 1: 1179, 1995
64. Suto, R. and Srivastava, P. K.: A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science, 269: 1585, 1995
65. Yedavelli, S. P., Guo, L., Daou, M. E., Srivastava, P. K., Mittelman, A. and Tiwari, R. K.: Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model. Int J Mol Med, 4: 243, 1999
66. Mincheff, M., Tchakarov, S., Zoubak, S., Loukinov, D., Botev, C., Altankova, I. et al: Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol, 38: 208, 2000
67. Chen, S. A., Tsai, M. H., Wu, F. T., Hsiang, A., Chen, Y. L., Lei, H. Y. et al: Induction of antitumor immunity with combination of HER2/neu DNA vaccine and interleukin 2 gene-modified tumor vaccine. Clin Cancer Res, 6: 4381, 2000
68. Sanda, M. G., Smith, D. C., Charles, L. G., Hwang, C., Pienta, K. J., Schlom, J. et al: Recombinant vaccinia-PSA (PROST-VAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology, 53: 260, 1999
69. Eder, J. P., Kantoff, P. W., Roper, K., Xu, G. X., Bubley, G. J., Boyden, J. et al: A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res, 6: 1632, 2000
70. Burch, P. A., Breen, J. K., Buckner, J. C., Gastineau, D. A., Kaur, J. A., Laus, R. L. et al: Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res, 6: 2175, 2000
71. Small, E. J., Fratesi, P., Reese, D. M., Strang, G., Laus, R., Peshwa, M. V. et al: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol, 18: 3894, 2000
72. Fong, L., Brockstedt, D., Benike, C., Breen, J. K., Strang, G., Ruegg, C. L. et al: Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol, 167: 7150, 2001
73. Tjoa, B. A., Simmons, S. J., Elgamal, A., Rogers, M., Ragde, H., Kenny, G. M. et al: Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate, 40: 125, 1999
74. Lodge, P. A., Jones, L. A., Bader, R. A., Murphy, G. P. and Salgaller, M. L.: Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res, 60: 829, 2000
75. Nishiyama, T., Tachibana, M., Horiguchi, Y., Nakamura, K., Ikeda, Y., Takesako, K. et al: Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res, 7: 23, 2001
76. Holtl, L., Rieser, C., Papesh, C., Ramoner, R., Herold, M., Klocker, H. et al: Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol, 161: 777, 1999
77. Kugler, A., Stuhler, G., Walden, P., Zoller, G., Zobywalski, A., Brossart, P. et al: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med, 6: 332, 2000